, Volume 77, Issue 15, pp 1665–1675 | Cite as

Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids

Adis Drug Evaluation


Oral ulipristal acetate (Esmya®; Fibristal®), a synthetic selective progesterone receptor modulator, is the first selective progesterone modulator to be approved for the treatment of uterine fibroids. It was initially approved for the preoperative treatment of moderate to severe uterine fibroid symptoms in women of reproductive age. Recently, the indication was extended in the EU to include the intermittent treatment of moderate to severe uterine fibroid symptoms. This narrative review summarizes pharmacological, efficacy and tolerability data relevant to the preoperative and intermittent use of ulipristal acetate in patients with symptomatic uterine fibroids. Ulipristal acetate is an effective and generally well tolerated treatment for patients with symptomatic uterine fibroids, both as preoperative, single-course treatment and as intermittent, longer-term treatment. It is noninferior in efficacy to intramuscular leuprolide acetate, as a preoperative treatment, and is associated with a lower rate of hot flashes, a common adverse event with gonadotropin-releasing hormone analogues. Thus, ulipristal acetate is an effective option for both preoperative and intermittent treatment of moderate to severe, symptomatic uterine fibroids in women of reproductive age.



During the peer review process, the manufacturer of ulipristal acetate was also offered the opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflicts of interest

Karly P. Garnock-Jones and Sean T. Duggan are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at


  1. 1.
    Singh SS, Belland L. Contemporary management of uterine fibroids: focus on emerging medical treatments. Curr Med Res Opin. 2015;31(1):1–12.CrossRefPubMedGoogle Scholar
  2. 2.
    Marret H, Fauconnier A, Chabbert-Buffet N, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol. 2010;152(2):133–7.CrossRefPubMedGoogle Scholar
  3. 3.
    National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management. Clinical guideline cg44. 2016. Accessed 5 Apr 2017.
  4. 4.
    Croxtall JD. Ulipristal acetate: in uterine fibroids. Drugs. 2012;72(8):1075–85.CrossRefPubMedGoogle Scholar
  5. 5.
    European Medicines Agency. Esmya® (ulipristal acetate 5 mg tablets): EU summary of product characteristics. 2016. Accessed 15 Mar 2017.
  6. 6.
    Yun BS, Seong SJ, Cha DH, et al. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist. Eur J Obstet Gynecol Reprod Biol. 2015;191:62–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Horak P, Mara M, Dundr P, et al. Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo. Int J Endocrinol. 2012;2012:436174.Google Scholar
  8. 8.
    Cox J, Malik M, Britten-Webb J, et al. Ulipristal acetate inhibits extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized controlled trial [abstract]. Reprod Sci. 2015;22(1 Suppl):88A.Google Scholar
  9. 9.
    Courtoy GE, Donnez J, Marbaix E, et al. In vivo mechanisms of uterine fibroid volume reduction with ulipristal acetate treatment [abstract no. ES25-0451]. Gynecol Surg. 2016;13(Suppl 1):S69.Google Scholar
  10. 10.
    Courtoy GE, Donnez J, Marbaix E, et al. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril. 2015;104(2):426–34.e1.Google Scholar
  11. 11.
    Malik M, Britten JL, Cox J, et al. Cytokine regulation central to ulipristal mediated leiomyoma treatment [abstract no. P-466]. Fertil Steril. 2016;106(3 Suppl):e280.CrossRefGoogle Scholar
  12. 12.
    Whitaker LHR, Murray AA, Matthews R, et al. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium. Hum Reprod. 2017;32(3):531–43.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Williams AR, Bergeron C, Barlow DH, et al. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol. 2012;31(6):556–69.CrossRefPubMedGoogle Scholar
  14. 14.
    Ravet S, Munaut C, Blacher S, et al. Persistence of an intact endometrial matrix and vessels structure in women exposed to VA-2914, a selective progesterone receptor modulator. J Clin Endocrinol Metab. 2008;93(11):4525–31.CrossRefPubMedGoogle Scholar
  15. 15.
    Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2007;92(9):3582–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Pohl O, Osterloh I, Gotteland JP. Effects of erythromycin at steady-state concentrations on the pharmacokinetics of ulipristal acetate. J Clin Pharm Ther. 2013;38(6):512–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Pohl O, Osterloh I, Lecomte V, et al. Changes in gastric pH and in pharmacokinetics of ulipristal acetate: a drug-drug interaction study using the proton pump inhibitor esomeprazole. Int J Clin Pharmacol Ther. 2013;51(1):26–33.CrossRefPubMedGoogle Scholar
  18. 18.
    Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409–20.CrossRefPubMedGoogle Scholar
  19. 19.
    Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421–32.CrossRefPubMedGoogle Scholar
  20. 20.
    Fernandez H, Schmidt T, Powell M, et al. Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results. Eur J Obstet Gynecol Reprod Biol. 2017;208:91–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Murji A, Crosier R, Chow T, et al. Role of ethnicity in treating uterine fibroids with ulipristal acetate. Fertil Steril. 2016;106(5):1165–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Donnez J, Vazquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014;101(6):1565–73.e1-18.Google Scholar
  23. 23.
    Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103(2):519–27.e3.Google Scholar
  24. 24.
    Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016;105(1):165–73.e4.Google Scholar
  25. 25.
    Fauser BC, Donnez J, Bouchard P, et al. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PLoS ONE. 2017;12(3):e0173523.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    European Medicines Agency. European public assessment report (EPAR) for Esmya. 2015. Accessed 17 Aug 2017.
  27. 27.
    Raga F, Moscardo I, Cholvi S, et al. Does ulipristal acetate administration for symptomatic uterine fibroids impact ovarian reserve? [abstract]. In: 32nd Annual Meeting of the European Society of Human Reproduction and Embryology. 2016.Google Scholar
  28. 28.
    Davies J, Kadir RA. Heavy menstrual bleeding: an update on management. Thromb Res. 2017;151(Suppl 1):S70–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Perez-Lopez FR, Ornat L, Ceausu I, et al. EMAS position statement: management of uterine fibroids. Maturitas. 2014;79(1):106-16.Google Scholar
  30. 30.
    Czuczwar P, Wozniak S, Szkodziak P, et al. Influence of ulipristal acetate therapy compared with uterine artery embolization on fibroid volume and vascularity indices assessed by three-dimensional ultrasound: prospective observational study. Ultrasound Obstetr Gynecol. 2015;45(6):744–50.CrossRefGoogle Scholar
  31. 31.
    Bizzarri N, Ghirardi V, Remorgida V, et al. Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study. Eur J Obstet Gynecol Reprod Biol. 2015;192:22–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Luyckx M, Squifflet J-L, Jadoul P, et al. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril. 2014;102(5):1404–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations